Quick Answer
Prime Medicine, Inc. reported Cash and Equivalents of $63.03 million for fiscal year 2025.
Prime Medicine, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $63.03M | -65.5% |
| 2024 | $182.48M | +338.9% |
| 2023 | $41.57M | -77.8% |
| 2022 | $187.62M | +1.2% |
| 2021 | $185.42M | +401.5% |
| 2020 | $36.98M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $71.40M | -39.5% | +32.7% |
| June 30, 2025 | $53.80M | -3.2% | -41.4% |
| March 31, 2025 | $91.88M | -2.4% | -49.6% |
| December 31, 2024 | $182.48M | +338.9% | +54.7% |
| September 30, 2024 | $117.98M | +168.4% | +112.2% |
| June 30, 2024 | $55.60M | -53.9% | -41.0% |
| March 31, 2024 | $94.16M | -29.4% | +126.5% |
| December 31, 2023 | $41.57M | -77.8% | -5.4% |
- Prime Medicine, Inc. showed a decrease of -65.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Prime Medicine, Inc.’s cash and equivalents has grown by 70.5% (from $36.98 million to $63.03 million).
- The most recent figure is from Prime Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: